Olanzapine: A new antipsychotic agent with efficacy in the management of schizophrenia

Annals of Pharmacotherapy

Volumn 31, Issue 11, 1997, Pages 1325-1334

  Kando, Judith C ^a,b,c   Shepski, John C ^b,c,d   Satterlee, Winston ^e   Patel, Jayendra K ^b,c   Reams, Stephen G ^e   Green, Alan I ^b,c  

^a Massachusetts Project   (United States)

^b MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Medical Management   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Olanzapine; Schizophrenia

Indexed keywords

AMINOTRANSFERASE; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; RITANSERIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG SAFETY; ENURESIS; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; META ANALYSIS; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; WEIGHT GAIN;

EID: 0030698293     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101110     Document Type: Review

References (61)

1. Donaldson SR, Gelenberg AJ, Baldessarini RJ. The pharmacological treatment of schizophrenia: a progress report. Schizophr Bull 1983;9: 504-27.
2. Hogarty G. Treatment and course of schizophrenia. Schizophr Bull 1977;3:587-99.
3. Breier A, Schreiber J, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991;48:239-46.
4. Sovner R, DiMascio A. Extrapyramidal syndromes and other neurological side effects of psychotropic drugs. In: Lipton MA, DiMascio A, Killam F, eds. Psychopharmacology: a generation of progress. New York: Raven Press 1978;1021-32.
5. Baldessarini RJ. A summary of current knowledge of tardive dyskinesia. Encephale 1988;14:263-8.
6. Levenson J. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-45.
7. Kane JM, Honingfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
8. Green AI. Treatment-resistant and treatment-intolerant schizophrenia. J Clin Psychiatry Monograph 1996;14:8-9.
9. Meltzer HY. Suicidality and clozapine. J Clin Psychiatry Monograph 1996;14:13-5.
10. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-90.
11. Meltzer HY. Clozapine and other atypical neuroleptics: efficacy, side effects, optimal utilization. J Clin Psychiatry 1994;12:38-42.
12. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994;55(9,suppl B):161-5.
13. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-8.
14. Baldessarini RJ, Frankenburg FR. Clozapine, a novel antipsychotic agent. New Engl J Med 1991;324:746-54.
15. Claus A, Bollen J, DeCuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305.
16. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
17. Cardoni AA. Risperidone: review and assessment of its role in the treatment of schizophrenia. Ann Pharmacother 1995;29:610-8.
18. Cavallaro R, Colombo C, Smeraldi E. A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Hum Psychopharmacol 1995;10:231-4.
19. Lacey RL, Preskorn SH, Jerkovich GS. Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics (letter)? Am J Psychiatry 1995;152:1401.
20. Satterlee W, Dellva MA, Beasely CM, Tran DV, Cousins LM, Tollefson GD. Effectiveness of olanzapine in long-term continuation therapy (poster). Presentation at the New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL, 1996.
21. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 1995;15(suppl 1):24S-9S.
22. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic. J Pharmacol Exp Ther 1992;262:545-51.
23. Bymaster FP, Calligaro DO, Falcone JF. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
24. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993;112:285-92.
25. Ereshefsky L, LaCombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993;38(suppl 3):S80-8.
26. Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992; 77:87-93.
27. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104.
28. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221: 1054.
29. Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia. Harv Rev Psychiatry 1996;3:241-53.
30. Olney JW, Farbe NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995;52:998-1007.
31. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995;122:198-201.
32. Obermeyer BD, Nyhart EH Jr, Mattiuz EL, Goodwin RM, Barton RD, Breau AP. The disposition of olanzapine (OL) in healthy volunteers. Pharmacologist 1993;35:176.
33. Package insert. Olanzapine. Indianapolis, IN: Eli Lilly and Co., 1996.
34. Ring BJ, Catlow J, Lindsay TJ, Gillepsie T, Roskos LK, Cerimele BJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
35. Patel BR, Nyhart EH, Callaghan JT, Kassahun K, Hunt TL, Kurtz D, et al. Combined population analysis of olanzapine in healthy volunteers. Pharm Res 1995;12:S-415.
36. Bergstrom RF, Callaghan JT, Cerimele BJ, Nyhart EH, Kassahunk, Hunt TL, et al. Pharmacokinetics of olanzapine in elderly and young. Pharm Res 1995;12:S-358.
37. Beasley CM Jr, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-23.
38. Beasley CM Jr, Sanger T, Satterlee W, Tolfeson G, Tran P, Hamilton S, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-67.
39. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
40. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamara RN. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
41. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
42. Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982;39:784-8.
43. Tollefson G, Lu Y. Comorbid mood disturbance in schizophrenia (poster). Presented at the Collegium International Neuro-Psychopharmacologicum (CINP), Melbourne, Australia, 1996.
44. Tran P, Beasley CM, Tollefson G, Crawford AM, Dellva MA, Gusman S, et al. Acute and long-term results of the dose ranging double-blind olanzapine trial (poster). Presented at the Collegium International Neuro-Psychopharmacologicum (CINP), Melbourne, Australia, 1996.
45. Tran PV, Beasley CM, Dellva MA, Cousins LM, Gusman S, Tollefson GD. Long-term efficacy and safety of olanzapine (poster). Presented at the American Psychiatric Association Meeting, Washington, DC, 1995.
46. Tran PV, Beasley CM, Dellva MA, Cousins LM, Gusman ST, Tollefson GD. Long-term efficacy and safety of olanzapine (poster). Presented at the American College of Neuropsychopharmacology (ACNP) meeting, San Juan, Puerto Rico, 1995.
47. Ring BJ, Binkley SN, Vanderbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2D6, and CYP3A. Br J Clin Pharmacol 1996;41: 181-6.
48. Rockhart DA. Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol 1996;16:101-2.
49. Bergstrom RF, Callaghan JT, Cerimele BJ, Nyhart EH Jr, Kassahun K, Hunt TL. Pharmacokinetics of olanzapine in elderly and young (abstract). Pharm Res 1995;12:S358.
50. Satterlee W. Unpublished report: olanzapine in elderly psychotic patients. Indianapolis, IN: Eli Lilly and Co., 1996.
51. Tran PV, Tollefson G, Hamilton S, Kuntz A. Olanzapine vs. risperidone in the treatment of psychosis. Preliminary report (poster). Presented at the American College of Neuropharmacology (ACNP) meeting, San Juan, Puerto Rico, 1996.
52. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
53. Kane JM, Cooper TB, Sachar EJ, Halpern FS, Bailine SL. Clozapine plasma levels and prolactin response. Psychopharmacology 1981;73: 184-7.
54. Jeste DV, Wyatt RJ. Understanding and treating tardive dyskinesia. New York: Guildord Press, 1982.
55. Addington DE, Toews JA, Addington JM. Risperidone and tardive dyskinesia: a case report. J Clin Psychiatry 1995;56:484-5.
56. Kane JM, Woerner MG, Pollack S, Safferman AZ, Liebermann JA. Does clozapine cause tardive dyskinesia? J Clin Psychiatry 1993;54:327-30.
57. Lader MH. Neuroleptic-induced deficit syndrome (NIDS). J Clin Psychiatry 1993;54:493-500.
58. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA. Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995;152:827-32.
59. Haller E, Binder RL. Clozapine and seizures. Am J Psychiatry 1990;147: 1069-71.
60. Devinsky O, Honingfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-71.
61. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital stays in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-26.